Anaphylaxis After Immunization of Children and Adolescents in Germany

Oberle, Doris; Pavel, Jutta; Rieck, Thorsten; Weichert, Stefan; Schroten, Horst; Keller‐Stanislawski, Brigitte; Tenenbaum, Tobias

doi:10.1097/inf.0000000000001073

Cited by 19 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study 98 investigated the annual frequency of anaphylaxis following immunization, a rare AE which can be life-threatening and causes hospitalization within 48 hours after immunization. The study was conducted on subjects younger than 18 years in Germany between June 2008 and May 2010.…”

Section: Vaccine Types and Production Methodsmentioning

confidence: 99%

Influenza vaccines: Evaluation of the safety profile

Trombetta

Gianchecchi

Montomoli

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The safety of vaccines is a critical factor in maintaining public trust in national vaccination programs. Vaccines are recommended for children, adults and elderly subjects and have to meet higher safety standards, since they are administered to healthy subjects, mainly healthy children. Although vaccines are strictly monitored before authorization, the possibility of adverse events and/or rare adverse events cannot be totally eliminated.Two main types of influenza vaccines are currently available: parenteral inactivated influenza vaccines and intranasal live attenuated vaccines. Both display a good safety profile in adults and children. However, they can cause adverse events and/or rare adverse events, some of which are more prevalent in children, while others with a higher prevalence in adults.The aim of this review is to provide an overview of influenza vaccine safety according to target groups, vaccine types and production methods.

show abstract

Section: Vaccine Types and Production Methodsmentioning

confidence: 99%

Influenza vaccines: Evaluation of the safety profile

Trombetta

Gianchecchi

Montomoli

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…are a known and reported adverse event related to immunization, 13 but such events are exceedingly rare, occurring after <1 per million doses of vaccines administered. 23,[82][83][84][85] Guillain-Barré syndrome suspected as a [161][162][163] MMR = measles, mumps, rubella; MMRV = measles, mumps, rubella, varicella; DTaP= diphtheria, tetanus and acellular pertussis; Tdap = tetanus, diphtheria and acellular pertussis; OPV = oral polio vaccine; HPV = human papilloma virus FIGURE 3 Disseminated papular rash after receipt of smallpox vaccine (ACAM2000), without detectable intralesional virus 37 vaccine-associated event through case reports. 36,86,87 Symptoms include progressive neuromuscular weakness, usually beginning in the extremities and then centrally, with potential progression toward respiratory failure or cranial nerve weakness.…”

Section: Guillain-barré Syndromementioning

confidence: 99%

Immune‐mediated adverse reactions to vaccines

Stone

Rukasin

Beachkofsky

et al. 2019

Brit J Clinical Pharma

148

171

View full text Add to dashboard Cite

Vaccination continues to be the single most important and successful public health intervention, due to its prevention of morbidity and mortality from prevalent infectious diseases. Severe immunologically mediated reactions are rare and less common with the vaccine than the true infection. However, these events can cause public fearfulness and loss of confidence in the safety of vaccination. In this paper, we perform a systematic literature search and narrative review of immune-mediated vaccine adverse events and their known and proposed mechanisms, and outline directions for future research.Improving our knowledge base of severe immunologically mediated vaccine reactions and their management drives better vaccine safety and efficacy outcomes.

show abstract

“… 10 Also in Germany, except for the influenza A virus subtype (H1N1) pandemic influenza vaccination, it was estimated at 6.8 cases per year. 11 In the previous study 2009–2013 in Korea, vaccines had been reported being responsible for 1.0 percent of the cases. 12 However, this was limited in identifying the frequency of vaccine anaphylaxis because it was a report by a small number of medical institutions and the result was a code analysis using the International Classification of Diseases, 10th Revision (ICD-10), but not a BCCD based analysis.…”

Section: Discussionmentioning

confidence: 96%

“…In the US, anaphylaxis by inactivated trivalent influenza vaccine and monovalent were 1.35 and 1.83 per million doses, respectively, and in Germany, anaphylaxis was most common after the immunization of the pandemic H1N1 influenza vaccine. 10 11 One study found that seven out of 10 cases of vaccine anaphylaxis were caused by influenza vaccines in Korea. 12 …”

Section: Discussionmentioning

confidence: 99%

Vaccine-related Anaphylaxis Cases Confirmed by KCDC from 2001-2016

et al. 2020

View full text Add to dashboard Cite

Background: A national immunization program (NIP) to prevent disease and reduce mortality from vaccine preventable diseases (VPD) is very important. Methods: We analyzed only the anaphylaxis cases that occurred between 2001 and 2016 that Korea Centers for Disease Control and Prevention (KCDC) determined had a definite causal relationship with a vaccine. The clinical symptoms were assessed according to the Brighton Collaboration case definition (BCCD) level. Results: During the period, there were 13 cases of vaccine-related anaphylaxis. The median age was 9 years (range, 1 month to 59 years). The incidence of anaphylaxis per million doses was 0.090 in 2005, 0.079 in 2012, 0.071 in 2013, 0.188 in 2015, and 0.036 in 2016. Of those cases, 23.1% were influenza vaccines, and 76.9% were BCCD level 2. Epinephrine was used in 46.2%. Conclusion: Vaccine-related anaphylaxis seems to have been very rare in the past, but health care professionals must always be aware of anaphylaxis.

show abstract

Anaphylaxis After Immunization of Children and Adolescents in Germany

Abstract: This study confirms that anaphylaxis after immunization in children and adolescents is a rare event. AS03 adjuvanted A/H1N1 pandemic influenza vaccine seems to be associated with a higher risk of anaphylaxis when compared with other vaccines.

Cited by 19 publications

References 20 publications

Influenza vaccines: Evaluation of the safety profile

Influenza vaccines: Evaluation of the safety profile

Immune‐mediated adverse reactions to vaccines

Vaccine-related Anaphylaxis Cases Confirmed by KCDC from 2001-2016

Contact Info

Product

Resources

About